Low prevalence of asthma in Mexican children and adults with a positive rtRT-PCR test for SARS-CoV-2: a cross-sectional study during the 2020 pandemic

Main Article Content

Martín Bedolla-Barajas
Jaime Morales-Romero https://orcid.org/0000-0002-1492-1797
Tonatiuh Ramses Bedolla-Pulido https://orcid.org/0000-0002-5292-0728
Carlos Meza-López https://orcid.org/0000-0002-8720-4289
Martín Robles-Figueroa https://orcid.org/0000-0003-3984-9928
Norma Angélica Pulido-Guillén
Luis Gustavo Orozco-Alatorre https://orcid.org/0000-0002-3037-5124
Carlos Alberto Andrade-Castellanos https://orcid.org/0000-0003-4720-3289

Keywords

asthma, COVID-19, cross-sectional study, children, adults

Abstract

Background: It has recently been argued that asthma does not increase the risk of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. If so, the prevalence of asthma in subjects diagnosed with COVID-19 should be lower than in the general population.


Objective: To determine the prevalence of asthma in Mexican children and adults with SARS-CoV-2 infection.


Methods: A public database of the Epidemiological Surveillance System for Viral Respiratory Disease in Mexico was analyzed. Those who underwent the real-time reverse transcriptase-polymerase chain reaction-SARS-CoV-2 (rtRT-PCR-SARS-CoV-2) test from February 27 to June 21, 2020, were included. In addition to the prevalence of asthma, some factors associated with it were investigated.


Results: Data from 417,366 subjects were analyzed. Asthma prevalence in children, adults, and global were 3.7%, 3.3%, and 3.3%, respectively. Although the asthma prevalence was lower in SARS-CoV-2 positive over negative patients, significant differences were only found in adults (2.8% vs. 3.7% respectively; odds ratio (OR) = 0.74; 95% confidence interval (CI): 0.71–0.77); but not in children (3.5% vs. 3.8%, respectively; OR = 0.91; 95%CI: 0.76–1.10). Multivariate analysis showed in younger than 18 years that girls and immunosuppression were factors associated with a decrease in the odds to develop asthma. In adults, asthma was positively associated with females, obesity, smoking, immunosuppression, chronic obstructive pulmonary disease, arterial hypertension, and cardiovascular disease.


Conclusion: The prevalence of asthma in child and adult were lower than those previously reported. Our study seems to support the hypothesis that asthma patients have a lower risk of SARS-CoV-2 infection. Further studies are required to demonstrate the consistency of our findings.

Abstract 1293 | PDF Downloads 941 HTML Downloads 202 XML Downloads 187

References

1. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1211–59. 10.1016/S0140-6736(17)32154-2

2. Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S, et al. Global variation in the prevalence and severity of asthma symptoms: Phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2009;64:476–83. 10.1136/thx.2008.106609

3. To T, Stanojevic S, Moores G, Gershon AS, Bateman ED, Cruz AA, et al. Global asthma prevalence in adults: Findings from the cross-sectional world health survey. BMC Public Health. 2012;12:204. 10.1186/1471-2458-12-204

4. Al Huraimel K, Alhosani M, Kunhabdulla S, Stietiya MH. SARS-CoV-2 in the environment: Modes of transmission, early detection and potential role of pollutions. Sci Total Environ. 2020;744:140946. 10.1016/j.scitotenv.2020.140946

5. Novak N, Cabanillas B. Viruses and asthma: The role of common respiratory viruses in asthma and its potential meaning for SARS-CoV-2. Immunology. 2020;161(2):83–93. 10.1111/imm.13240

6. Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) — China, 2020]. Zhonghua Liu Xing Bing Xue Za Zhi. 2020; 41(2):113–22. Chinese. 10.3760/cma.j.issn.0254-6450.2020.02.003.

7. Li X, Xu S, Yu M, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020;146:110–18. 10.1016/j.jaci.2020.04.006

8. Mancilla-Hernaández E, Gonzaález-Soloárzano EVM, Medina-Aávalos MAá, Barnica-Alvarado RH. Prevalencia de asma y sus siáíntomas en poblacioáón escolar de Cuernavaca, Morelos, Meáéxico [Prevalence of asthma and its symptoms in schoolchildren from Cuernavaca, Morelos, Mexico]. Rev Alerg Mex. 2016;63:351–57.Spanish.10.29262/ram.v63i4.189

9. Bedolla-Barajas M, Javier Ramírez-Cervantes F, Morales-Romero J, Jesús Pérez-Molina J, Meza-López C, Delgado-Figueroa N. A rural environment does not protect against asthma or other allergic diseases amongst Mexican children. Allergol Immunopathol. 2018;46:31–38. 10.1016/j.aller.2017.01.010

10. Morales-Romero J, Bedolla-Barajas M, Loáópez-Cota GA, Bedolla-Pulido TI, Bedolla-Pulido TR, Navarro-Lozano E, et al. Tendencia de la prevalencia de asma y sus síntomas en los adolescentes tardíos mexicanos en un periodo de siete años [Trends in the prevalence of asthma and its symptoms in Mexican late adolescents over a 7-year period]. Rev Alerg Mex. 2018;65:331–40. Spanish. 10.29262/ram.v65i4.392

11. Del-Rio-Navarro BE, Navarrete-Rodríguez EM, Berber A, Reyes-Noriega N, García-Marcos Álvarez L; et al. The burden of asthma in an inner-city area: A historical review 10 years after Isaac. World Allergy Organ J. 2020;13:100092. 10.1016/j.waojou.2019.100092

12. García-Sancho C, Fernández-Plata R, Martínez-Briseño D, Franco-Marina F, Pérez-Padilla JR. Prevalencia y riesgos asociados con pacientes adultos con asma de 40 años o más de la Ciudad de México: Estudio de base poblacional [Prevalence and risks associated with adult patients with asthma aged 40 years or more from Mexico City: A population-based study]. Salud Publica Mex. 2012;54:425–32. Spanish. 10.1590/s0036-36342012000400013

13. Bedolla-Barajas M, Valdez-López F, Alcalá-Padilla G, Bedolla-Pulido TI, Rivera-Mejia V, Morales-Romero J. Prevalence and factors associated to peanut allergy in Mexican school children. Allergol Immunopathol. 2017;45:69–76. 10.1016/j.aller.2016.04.013

14. Bedolla-Barajas M, Macriz-Romero N, Jara-Ettinger AC, Macriz-Romero M, Fregoso-Fregoso M, Morales-Romero J. Autorreporte de alergia al látex en estudiantes de medicina: Prevalencia y factores asociados [Self-report of latex allergy in medical students: Prevalence and associated factors]. Rev Alerg Mex. 2018;65:10–18. Spanish. 10.29262/ram.v65i1.290

15. Halpin DMG, Faner R, Sibila O, Badia JR, Agusti A. Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection? Lancet Respir Med. 2020;8:436–8. 10.1016/S2213-2600(20)30167-3

16. Zhu Z, Hasegawa K, Ma B, Fujiogi M, Camargo CA Jr, Liang L. Association of asthma and its genetic predisposition with the risk of severe COVID-19. J Allergy Clin Immunol. 2020;46(2):327-9.e4.. 10.1016/j.jaci.2020.06.001

17. Jackson DJ, Busse WW, Bacharier LB, Kattan M, O’Connor GT, Wood RA, et al. Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2. J Allergy Clin Immunol. 2020;146:203–206.e3. 10.1016/j.jaci.2020.04.009

18. Abiad HF, Alameddine VM, Hallit S, Torbey P-H, Mroueh S, Yazbek N, et al. Aeroallergen sensitization in Lebanese asthmatic children: the results of a cohort national study. Environ Sci Pollut Res Int. 2020;27:5597–605. 10.1007/s11356-019-07234-z

19. Kwizera R, Wadda V, Mugenyi L, Aanyu-Tukamuhebwa H, Nyale G, Yimer G, et al. Skin prick reactivity among asthmatics in East Africa. World Allergy Organ J. 2020;13:100130. 10.1016/j.waojou.2020.100130

20. Zhang J-J, Dong X, Cao Y-Y, Yuan Y-D, Yang Y-B, Yan Y-Q, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020;75:1730–41. 10.1111/all.14238

21. Green I, Merzon E, Vinker S, Golan-Cohen A, Magen E. COVID-19 susceptibility in bronchial asthma. J Allergy Clin Immunol Pract. 2021; 9(2):684–92. . 10.1016/j.jaip.2020.11.020.

22. Grandbastien M, Piotin A, Godet J, Abessolo-Amougou I, Ederlé C, Enache I, et al. SARS-CoV-2 Pneumonia in Hospitalized Asthmatic Patients Did Not Induce Severe Exacerbation. J Allergy Clin Immunol Pract. 2020;8:2600-7. 10.1016/j.jaip.2020.06.032.

23. Chhiba KD, Patel GB, Vu THT, Chen MM, Guo A, Kudlaty E, et al. Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19. J Allergy Clin Immunol. 2020;146:307–314.e4. 10.1016/j.jaci.2020.06.010.

24. Lieberman-Cribbin W, Rapp J, Alpert N, Tuminello S, Taioli E. The impact of asthma on mortality in patients with COVID-19. Chest. 2020; 158(6): 2290–1. 10.1016/j.chest.2020.05.575.